Clozapine: Current status and role in the pharmacotherapy of schizophrenia

Canadian Journal of Psychiatry

Volumn 41, Issue 3, 1996, Pages 161-166

  Remington, Gary J ^a,f   Addington, Donald ^b   Collins, Evan J ^a   Jones, Barry D ^c   Lalonde, Pierre ^d   Maccrimmon, Duncan J ^d   William Macewan, G ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

HUMAN; REVIEW; SCHIZOPHRENIA;

EID: 0030000986     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674379604100306     Document Type: Review

References (72)

1. Meltzer HY. Novel approaches to the pharmacotherapy of schizophrenia. Drug Development Research 1986;9:23-40.
2. Karte J, Honigfeld G, Singer J, and others. Clozapine for treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
3. Meltzer HY, Bastani B, Kwon KY, and others. A prospective study of clozapine in treatment resistant schizophrenia. 1: preliminary report. Psychopharmacology (Berl) 1989;99(Supp1):68S-72S.
4. Ereshefsky L, Watanabe MD. Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharmacol Ther 1989;8:691-709.
5. Stephens P. A review of clozapine: an antipsychotic for treatment-resistant schizophrenia. Compr Psychiatry 1990;31-315-326.
6. Baldessarini RJ. Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;324:746-754.
7. Jann MW. Clozapine. Pharmacotherapy 1991;11:179-195.
8. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992:160(17 Suppl):41-45.
9. Small JG. Milstein V, Marhenke JD. and others. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987;48:263-267.
10. Casey D. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989;99:47S-53S.
11. Lieberman J, Johns C, Cooper T, and others. Clozapine pharmacology and tardive dyskinesia. Psychopharmacology 1989;99:54S-59S.
12. Naber D, Leppig M, Grohmann R, and others. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia-a retrospective study of 387 patients. Psychopharmacology 1989;99:73S-76S.
13. "Naber D, Hippius II. Efficacy and tolerability of clozapine in the treatment of 425 schizophrenic patients. Schizophr Res 1991;4:322-323.
14. 2 antagonism in extrapyramidal functions. Br J Psychiatry 1992;160 (17 Suppl):34S-37S.
15. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:18S-27S.
16. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 1989;99:28S-31S.
17. Meltzer HY, Bastani B, Ramirez L, and others. Clozapine: new research on efficacy and mechanism of action. European Archives of Psychiatry and Neurological Science 1989;238:332-339.
18. Coward DM. General pharmacology of clozapine. Br J Psychiatry 1992;160(17 Suppl):5S-11S.
19. Shaikh S, Collier D, Kerwin RW, and others. Dopamine D4 receptor subtypes and response to clozapine. Lancet 1993;341:116.
20. Westlin WF. Comments by a Sandoz official. Hosp Community Psychiatry 1990;41:874-876.
21. Alvin JMJ, Lieberman JA, Safferman AZ, and others. Clozapine-induced agranulocytosis. N Engl J Medicine 1993;329:162-167.
22. Aitken D. Sandoz Canada, Inc. Medical Communications Department Dorval (QC), 1994.
23. Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 1992;160(17 Suppl):38S-40S.
24. Pelonero AL, Elliot RL. Ethical and clinical considerations in selecting patients who will receive clozapine. Hosp Community Psychiatry 1990;41:878-880.
25. Collins EJ, Lalonde P, Jones BD, and others. Clozapine in the treatment of refractory schizophrenia: Canadian policies and clinical guidelines. Can J Psychiatry 1992;37:482-488.
26. Terkelsen KG, Grosser RC. Estimating clozapine's cost to the nation. Hosp Community Psychiatry 1990;41:863-869.
27. Revicki DA, Luce BR, Weschter JM, and others. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41:850-854.
28. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry 1990;41:882-885.
29. Meltzer HY, Cola P. Way L, and others. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638.
30. Remillard AJ. Johnson JJ. A pharmacoeconomic evaluation of clozapine in one patient. Canadian Journal of Hospital Pharmacy 1993;46:115-119.
31. Meltzer HY, Burnett S, Bastani B, and others. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-897.
32. Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry 1989;46:672.
33. 3. Kuoppasalmi K, Rimon R, Naukkarinen H, and others. The use of clozapine in treatment-refractory schizophrenia Schizophr Res 1993;10:29-32.
34. Brier A, Buchanan RW, Irish D, and others. Clozapine treatment of outpatients with schizophrenia, 2: outcomes and long-term response patterns. Hosp Community Psychiatry 1993;44:1145-1149.
35. Krogh CME, editor. Compendium of pharmaceuticals and specialties, 28th ed. Ottawa: Canadian Pharmaceutical Association; 1994 p 262-264.
36. Davis JM, Casper R. Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 1977;14:260-282.
37. Kane JM, Marder SR. Response to Fuchs. Schizophr Bull 1994;20:23-24.
38. Brenner HD, Dencker SJ, Goldstein MJ. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16:551-561.
39. Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992;18:515-542.
40. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
41. Chouinard G, Ross-Chouinard A, Annable L, and others. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233.
42. Guy W, editor. ECDEU assessment manual for psychopharmacology, revised. Rockville (MD): National Institute of Mental Health; 1976. (DHEW publication no. ADM 76338).
43. Heinrichs DW. Hanlon TE, Carpenter WT Jr. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-398.
44. Wallace CJ. Functional assessment in rehabilitation. Schizophr Bull 1986;12:604-630.
45. Greenberg R, Goldberg TE, Griffin S, and others. Effects of clozapine on cognition in patients with schizophrenia. Schizophr Res 1991;4:385.
46. Kenny JT, Friedman L, Ubogy D, and others. Differential effect of clozapine on psychopathology and cognitive dysfunction in treatment-resistant schizophrenics. Schizophr Bull 1991;4:386.
47. Kenny JT, Meltzer HY. Effect of atypical and typical antipsychotic drugs on neuropsychological functions in early-stage schizophrenic patients. Schizophr Res 1992;6:162.
48. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992;160(17 Suppl):40S-53S.
49. Williams R, Baillie P, Dickson RA, Dalby JT. Cognitive and behavioural efficacy of clozapine in clinical trials [letter]. Can J Psychiatry 1993;38:522.
50. Meltzer HY. Cognitive dysfunction and outcome in schizophrenia. Presented at the XIX Collegium Internationale Neuro-Psychopharmacologicum; 1994 June 27-July 1; Washington DC.
51. Smith GN, MacEwan GW. Ancill RJ. and others. Diagnostic confusion in treatment-refractory psychotic patients. J Clin Psychiatry 1992;53:197-200.
52. Wilson WH. Reassessment of state hospital patients diagnosed with schizophrenia. J Neuropsychiatry Clin Neurosci 1989;1:394-397.
53. Curry SH. Commentary: the strategy and value of neuroleptic drug monitoring. J Clin Psychopharmacol 1985;5:263-271.
54. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72.
55. Hoge SK, Applebaum PS, Lawlor T, and others. A prospective, multicentre study of patients' refusal of antipsychotic medications. Arch Gen Psychiatry 1990;47:949-956.
56. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1993;53:426-433.
57. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses. Arch Gen Psychiatry 1988;45:79-91.
58. Kane JM. Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993;19:287-302.
59. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50:329-338.
60. Remington GJ, Prendergast P, Bezchlibnyk-Butler KZ. Dosaging patterns in schizophrenia with depot, oral and combined neuroleptic therapy. Can J Psychiatry 1993;38:159-161.
61. Van Putten T, Marder SR, Wirsching WC, and others. Neuroleptic plasma levels. Schizophr Bull 1991;17:197-216.
62. Levinson DF, Simpson GM, Singh H, and others. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990;47:761-768.
63. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754-758.
64. Simpson GM. Wilson WH. Strategies for treating nonresponding schizophrenics. In: Schulz SC, Tamminga CA, editors. Schizophrenia: scientific progress. New York: Oxford University Press; 1989.
65. Osser DN. A systematic approach to pharmacotherapy in patients with neuroleptic-resistant psychoses. Hosp Community Psychiatry 1989;40:921-927.
66. Kinon BJ, Kane JM. Johns C, and others. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993;29:309-314.
67. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;2:325-351.
68. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments in schizophrenia. Schizophr Bull 1991;17:217-245.
69. Claus A, Bollen J, De Cuyper H, and others. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
70. Chouinard G, Jones B, Remington G, and others. A Canadian multicenter study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-35.
71. Borison RL, Pathiraja AP, Diamond BL, and others. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-218.
72. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.